comparemela.com

Latest Breaking News On - Axicabtagene ciloleucel - Page 6 : comparemela.com

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Little rockUnited statesUniversity of arkansasAakash mukherjeeDepartment of internal medicineCollege of medicineWinthropp rockefeller cancer instituteWinthropp rockefeller cancer institute transplant centerCancer institute transplant centerCancer instituteMedical sciencesInternal medicineContributing kiteRelapsed refractoryb cell lymphomaPatients with relapsed refractory diffuse largeb cell lymphomaScholar 1 study

Kite announces completion of marketing authorization transfer for Yescarta CAR T-cell therapy in Japan

Santa Monica: Kite Pharma, Inc., a Gilead Company, has announced that the Marketing Authorization in Japan for Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has.

United statesEl segundoKennet brystingCindy perettieDaiichi sankyoKite pharma incGilead scienceskk weKite pharmaMarketing authorizationKite cell therapy business unitExecutive vice presidentGlobal headGeneral managerGilead sciencesGilead sciences newsCart cell therapy

Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes

The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).

United statesCarona jacobsonAmerican society of clinical oncology annual meetingHarvard medical schoolClinical oncology annualImmune effector cell therapy programDana farber cancer instituteHarvard medicalAxi celAxicabtagene ciloleucelCart cell therapy

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.

United statesGenentech rocheMorphosys incyteJason westinLymphoma clinical research programJanssen scientific affairsBristol myers squibbDepartment of lymphomaUniversity of texas md anderson cancer centerNew england journalAggressive lymphomaCancer centerBristol myersIksuda therapeuticsMonte rosa therapeuticsAxi cel

Gilead Sciences, Inc : Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA

- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:

United statesFoster cityCarol ohearFrank neumannJacquie rossBrexucabtagene autoleucelPivekimab sunirineAxicabtagene ciloleucelCressida robsonMeaghan smithDecitabine cedazuridineSanta monicaGlobal head of clinical developmentGilead sciencesGilead sciences incClinical development

vimarsana © 2020. All Rights Reserved.